FDA adviser resigns over approval of new Alzheimer's drug

www.cnn.com
3 min read
standard
A member of an FDA advisory committee said Wednesday he had resigned over the agency's approval of a new Alzheimer's drug.
(CNN) A member of a US Food and Drug Administration advisory committee said Wednesday he had resigned over the agency's approval of a new Alzheimer's drug.

The FDA approved aducanumab , to be sold under the brand name Aduhelm, this week over the objections of its advisory Peripheral and Central Nervous System Drugs Advisory Committee.

Mayo Clinic neurologist Dr. David Knopman told CNN Wednesday he had resigned from the committee in protest.

"I resigned from the PCNS committee because if I ever were asked to serve on a future panel, I wouldn't have wanted to be treated in the disrespectful way that the aducanumab external advisers were treated," he said via email.

"While I disagree with the decision to approve aducanumab, we in the clinical care and clinical research worlds will simply have to learn to adapt to the new circumstances."

The FDA's advisers said there wasn't enough evidence to support approving the drug, which is given by infusion. Initial trials of the treatment, meant to be given to people very early in the course of disease before they develop dementia, did not indicate it helped at…
Maggie Fox, CNN
Read full article